Grandfield & Dodd LLC Lowers Stock Position in Sanofi $SNY

Grandfield & Dodd LLC decreased its holdings in Sanofi (NASDAQ:SNY) by 0.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 385,188 shares of the company’s stock after selling 2,742 shares during the quarter. Grandfield & Dodd LLC’s holdings in Sanofi were worth $18,608,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of SNY. Nuveen LLC acquired a new stake in shares of Sanofi in the first quarter valued at approximately $177,831,000. Federated Hermes Inc. boosted its position in shares of Sanofi by 58.5% during the 1st quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company’s stock worth $218,933,000 after purchasing an additional 1,456,269 shares in the last quarter. OLD Mission Capital LLC purchased a new position in shares of Sanofi in the 1st quarter valued at about $48,938,000. Regal Partners Ltd lifted its stake in shares of Sanofi by 102.3% in the second quarter. Regal Partners Ltd now owns 1,548,204 shares of the company’s stock valued at $74,794,000 after purchasing an additional 782,838 shares during the period. Finally, Raymond James Financial Inc. grew its position in shares of Sanofi by 15.1% in the first quarter. Raymond James Financial Inc. now owns 3,244,027 shares of the company’s stock valued at $179,914,000 after purchasing an additional 425,597 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of research reports. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research report on Tuesday. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Sanofi has an average rating of “Buy” and an average target price of $62.67.

Sanofi Price Performance

SNY opened at $52.34 on Friday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $128.52 billion, a P/E ratio of 12.26, a PEG ratio of 1.38 and a beta of 0.49. The stock has a fifty day moving average of $48.89 and a 200-day moving average of $49.47.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 24th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The company had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.25 EPS. Equities analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.